Want to see SGMT full AI Analyst Report?
SGMT Stock Chart & Stats
$10.29
$0.06(0.86%)
At close: 4:00 PM EDT
$10.29
$0.06(0.86%)
Day’s Range― - ―
52-Week Range$4.50 - $11.45
Previous CloseN/A
Volume910.94K
Average Volume (3M)1.45M
Market Cap
$685.12M
Enterprise Value$172.39M
Total Cash (Recent Filing)$240.13M
Total Debt (Recent Filing)$1.94M
Price to Earnings (P/E)―
Beta2.72
Next Earnings
Nov 12, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding70,341,170
10 Day Avg. Volume1,443,206
30 Day Avg. Volume1,454,749
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.47
Forecast
1Y Price Target
$28.46Price Target Upside176.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low leverage gives Sagimet financial flexibility while it funds clinical development. A strong equity base and expanded assets reduce balance-sheet stress, allowing more capital to remain focused on trials, regulatory work, and pipeline advancement.
Clinical ProgressPositive late-stage data, an accepted Chinese NDA, and initiation of the U.S. Phase 3 study represent meaningful development progress. These milestones strengthen the commercial and regulatory foundation for denifanstat across multiple geographic markets.
Funding RunwayA funding runway extending into mid-2029 supports continued execution across denifanstat, TVB-3567, and topical FASN programs. This gives management time to pursue clinical milestones and potential partnerships without needing to immediately reprioritize development.
Bears Say
No Commercial ScaleSagimet has not yet established commercial revenue, while sizable operating and net losses continue. Until a candidate is approved and launched, the company lacks product-driven earnings support and remains dependent on successful future pipeline execution.
Persistent Cash BurnNegative operating and free cash flow show that development spending continues to consume capital rather than generate internally funded growth. Even with some improvement from 2025, sustained burn will require disciplined allocation and continued access to financing resources.
Unproven CommercializationThe company’s value remains tied to clinical and regulatory outcomes because its business is still centered on development rather than an established commercial portfolio. Delays or setbacks before approval could therefore postpone meaningful revenue generation and profitability.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $4.50 and its highest was $11.45 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $685.12M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Aug 11, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.251 by -$0.009.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.26.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 70,341,170 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.251. Following the earnings report the stock price went down -0.522%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.46 (176.61% Upside)
$28.46 (176.61% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $578.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.55%
12-Months-Change
Fundamentals
Return on Equity
-31.96%
Trailing 12-Months
Asset Growth
91.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$28.46
▲(176.61% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
4.64% Insiders
5.85% Mutual Funds
0.18% Other Institutional Investors
77.68% Public Companies and
Individual Investors